INDV vs. HIK, HCM, AMYT, BMK, APH, AGY, BXP, ANCR, EAH, and CEL
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Amryt Pharma (AMYT), Benchmark (BMK), Alliance Pharma (APH), Allergy Therapeutics (AGY), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), ECO Animal Health Group (EAH), and Celadon Pharmaceuticals (CEL). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Indivior (LON:INDV) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.
Indivior presently has a consensus target price of GBX 2,515, indicating a potential upside of 74.05%. Hikma Pharmaceuticals has a consensus target price of GBX 2,050, indicating a potential upside of 6.22%. Given Indivior's stronger consensus rating and higher possible upside, equities analysts plainly believe Indivior is more favorable than Hikma Pharmaceuticals.
Hikma Pharmaceuticals received 242 more outperform votes than Indivior when rated by MarketBeat users. However, 80.35% of users gave Indivior an outperform vote while only 70.56% of users gave Hikma Pharmaceuticals an outperform vote.
Indivior has a beta of 0.06, indicating that its stock price is 94% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.
In the previous week, Hikma Pharmaceuticals had 1 more articles in the media than Indivior. MarketBeat recorded 1 mentions for Hikma Pharmaceuticals and 0 mentions for Indivior. Hikma Pharmaceuticals' average media sentiment score of 0.59 beat Indivior's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the news media.
Hikma Pharmaceuticals has a net margin of 6.61% compared to Indivior's net margin of 0.44%. Indivior's return on equity of 12.20% beat Hikma Pharmaceuticals' return on equity.
Hikma Pharmaceuticals has higher revenue and earnings than Indivior. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.0%. Hikma Pharmaceuticals pays an annual dividend of GBX 57 per share and has a dividend yield of 3.0%. Indivior pays out 50,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals pays out 8,507.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Hikma Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.
85.6% of Indivior shares are held by institutional investors. Comparatively, 37.6% of Hikma Pharmaceuticals shares are held by institutional investors. 3.3% of Indivior shares are held by company insiders. Comparatively, 30.6% of Hikma Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Hikma Pharmaceuticals beats Indivior on 12 of the 20 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
